Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine

Xue Yan Wang¹
Margaret Lim-Jurado²
Narayanan Prepageran³
Pongsakorn Tantilipikorn⁴
De Yun Wang⁵

¹Department of Allergy, Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China; ²St Luke’s Medical Center, Quezon City, Manila, Philippines; ³Department of Otorhinolaryngology, Head & Neck Surgery, University Malaya Faculty of Medicine, Kuala Lumpur, Malaysia; ⁴Rhinology and Allergy Division, Department of Otorhinolaryngology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; ⁵Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Abstract: Allergic rhinitis and urticaria are common allergic diseases that may have a major negative impact on patients’ quality of life. Bilastine, a novel new-generation antihistamine that is highly selective for the H₁ histamine receptor, has a rapid onset and prolonged duration of action. This agent does not interact with the cytochrome P450 system and does not undergo significant metabolism in humans, suggesting that it has very low potential for drug–drug interactions, and does not require dose adjustment in renal impairment. As bilastine is not metabolized and is excreted largely unchanged, hepatic impairment is not expected to increase systemic exposure above the drug’s safety margin. Bilastine has demonstrated similar efficacy to cetirizine and desloratadine in patients with seasonal allergic rhinitis and, in a Vienna Chamber study, a potentially longer duration of action than fexofenadine in patients with asymptomatic seasonal allergic rhinitis. It has also shown significant efficacy (similar to that of cetirizine) and safety in the long-term treatment of perennial allergic rhinitis. Bilastine showed similar efficacy to levocetirizine in patients with chronic spontaneous urticaria and can be safely used at doses of up to fourfold higher than standard dosage (80 mg once daily). The fourfold higher than standard dose is specified as an acceptable second-line treatment option for urticaria in international guidelines. Bilastine is generally well tolerated, both at standard and at supratherapeutic doses, appears to have less sedative potential than other second-generation antihistamines, and has no cardiotoxicity. Based on its pharmacokinetic properties, efficacy, and tolerability profile, bilastine will be valuable in the management of allergic rhinitis and urticaria.

Keywords: bilastine, second-generation antihistamines, allergic rhinitis, urticaria

Introduction

The frequency and impact of allergic diseases are often underestimated.¹ A key facilitator of the allergic response is immunoglobulin E (IgE) that is present on the surface of mast cells and basophils.² Interaction of the allergen with IgE and its receptor complex leads to activation of these cells and release of the substances, including histamine, that cause allergic symptoms.²

Because of the central role of histamine in allergic responses, many allergic conditions are treated with antihistamines, including allergic rhinitis and urticaria.³,⁴ Antihistamines have been in clinical use for >70 years, and the pharmacological characteristics of these agents have been evolving over that time.⁵

The objective of this article is to review the current burden of allergic rhinitis and urticaria in Asia Pacific, to briefly describe the evolution of antihistamine pharmacology, and to systematically review the pharmacological characteristics and clinical results of bilastine, a new antihistamine that is highly selective for the H₁ histamine receptor.
Research methodology
For the systematic review of bilastine data, a PubMed search was undertaken of all publications including “bilastine” in the title and/or abstract. No date limits were applied. All preclinical and clinical trials were assessed for inclusion in the review. Attention was preferentially given to randomized controlled trials, with appropriate controls for variation and bias (eg, placebo group, blinding).

Burden of allergic diseases in Asia Pacific
Allergic rhinitis
Allergic rhinitis is a symptomatic condition of the nose caused by allergen exposure and IgE-mediated inflammation. Allergic rhinitis is defined as intermittent or persistent, and its severity is classed as mild or moderate-to-severe. Historically, symptoms of the condition were categorized as occupational, seasonal, or perennial, but this classification is now unsatisfactory because these categories are not necessarily mutually exclusive. In 2001, the document “Allergic rhinitis and its impact on asthma” (ARIA) recommended replacing the terms “seasonal” and “perennial” rhinitis by intermittent allergic rhinitis and persistent allergic rhinitis, respectively. Subsequently, “intermittent” and “persistent” are not precisely synonymous with seasonal and perennial allergic rhinitis.

Allergic rhinitis is frequently encountered in primary care. Patients report that allergic rhinitis has a marked detrimental effect on their sleep, social life, quality of life, and attendance and functioning at school and work. Another issue is that allergic rhinitis commonly coexists with other forms or allergic disease. Considerable clinical and epidemiological evidence also exists of an association between asthma and allergic rhinitis. It has been estimated that up to 75% of patients with asthma have rhinitis and that approximately one-third of patients with allergic rhinitis have asthma. Comorbid links between allergic rhinitis and sinusitis, conjunctivitis, otitis media, and nasal polyposis have been documented, although the extent of such links remains unclear. The economic burden of allergic rhinitis is frequently underrated, and indirect costs of the disorder are extensive.

Allergic rhinitis is a worldwide health problem, with a prevalence estimated at between 10% and 30%, and it is associated with considerable morbidity. The disorder is estimated to affect the lives of >500 million people worldwide. The burden is particularly high and increasing in Asia Pacific, where many people now live in crowded cities with high levels of environmental pollution. The Allergies in Asia Pacific survey reported an adult prevalence of 9% across the region, with 63% of patients having seasonal or intermittent allergies. However, the prevalence of allergic rhinitis subtypes does differ between countries in Asia Pacific. In several Southeast Asian surveys, ~70% of patients with allergic rhinitis had persistent disease and ~30% had intermittent symptoms, whereas in the People’s Republic of China, ~25% of patients with allergic rhinitis had the persistent form and 75% had intermittent disease.

Urticaria
Another common disease is urticaria. Patients with urticaria typically develop wheals (hives), angioedema, or both. Usually, about half of all patients with urticaria have associated angioedema. If the condition has a duration of <6 weeks, it is acute. If it persists for >6 weeks, or recurs, it is chronic. Symptoms of the disorder may endure for several months or years. The most frequent causes of acute urticaria, which may affect up to 15%–25% of all individuals at some stage in their lives, are viral infections (especially affecting the upper respiratory tract), food allergies, and drug adverse reactions. Physical effects, systemic disease, or long-term infection may also lead to urticaria/angioedema. In patients with chronic urticaria, the condition is often idiopathic (ie, has no discernible cause in ~55%–80% of cases); this is known as chronic spontaneous urticaria. The counterpart is chronic inducible urticaria, which is caused by physical stimuli such as cold, heat, sun, or pressure.

Unfortunately, there are limited data on the burden of urticaria in Asia Pacific. Internationally, chronic spontaneous urticaria is estimated to have a point prevalence of ~0.5%–1.0%. The peak age of occurrence is usually between 20 years and 40 years, and typical disease duration is 1–5 years, although this can be greater in many cases. As with allergic rhinitis, chronic urticaria is a devastating disorder that can have a major negative influence on a patient’s quality of life, including vitality, sleep, mobility, and social life. Because of emotional distress, patients with chronic spontaneous urticaria often have anxiety, depression, and somatoform disorders. As a result, the societal burden of the condition is great in terms of both direct and indirect health care costs. The disorder is often managed improperly, for example, with the repetitive use of oral corticosteroids that have significant safety concerns.
Role of histamine and the H₁ receptor subtype in IgE-mediated allergic diseases

Histamine has a key role in the pathophysiology of allergic inflammation.⁴ After exposure to an allergen, specific antibodies of the IgE type are produced in genetically predisposed individuals.⁴ These interact with receptors on the surface of basophils and mast cells. The consequence is a series of intracellular reactions culminating in exocytosis and the release of histamine and other inflammatory mediators such as platelet-activating factor and cytokines.⁴ Various drugs (eg, morphine) can also cause direct displacement of histamine from its storage granules.⁴

The consequences of histamine release include receptor-mediated smooth muscle cell contraction in the gastrointestinal and respiratory tracts, sensory nerve stimulation, vasodilation, plasma extravasation, and cellular recruitment, for example, to urticarial lesions.⁴ Various drugs (eg, morphine) can also cause direct displacement of histamine from its storage granules.⁴

Besides its mediating activity in the early allergic response, histamine contributes to the late allergic response by stimulating the production of cellular adhesion molecules, class II antigens, and cytokines.⁴

Four principal histamine receptor subtypes exist: H₁, H₂, H₃, and H₄. These are G-protein-coupled receptors that transfer extracellular signals via G proteins, which act as intermediaries between cell surface receptors and intracellular second messengers (Figure 1).⁴ H₁ and H₂ receptors are widely distributed throughout the body, but the H₃ subtype is mainly located in the central nervous system (CNS) and the H₄ subtype in hematopoietic tissues.⁴ The allergic response is primarily mediated by the H₁ receptor subtype.

H₁ receptors are ubiquitous and are found in the adrenal medulla, CNS, endothelial and epithelial cells, heart, immune cells, sensory nerves, and smooth muscle.⁴ In the CNS, most of the postsynaptic actions of histamine are mediated by H₁ receptors.⁴ This leads to activity on sleep–wake cycles and probably explains the sedative effects noted with first-generation antihistamines that cross the blood–brain barrier.⁴ Via H₁ receptors, histamine also causes smooth muscle cell contraction in the gastrointestinal and respiratory tracts and stimulation of sensory nerves. Outcomes include pruritus, sneezing, increased vascular permeability, and edema.⁴

Antihistamines are not structurally related to histamine and are not competitive antagonists of histamine binding.
History of antihistamines

Histamine was discovered in 1907 by Windaus and Vogt, after decarboxylation of the amino acid histidine. Thirty years later, in 1927, Emanuel identified histamine as a constituent in normal tissues, notably the lungs, and in 1937, Bovet and Staub discovered antihistamines by demonstrating that synthesized agents could block the effects of histamine. A few years later, in 1942, the first antihistamine, phenbenzamine (Antergan), was introduced into commercial use. This was closely followed by diphenhydramine, brompheniramine, and chlorpheniramine in the mid-1940s, promethazine later that decade, and hydroxyzine in the 1950s.

In 1957, Daniel Bovet received the Nobel Prize in Physiology or Medicine for his major therapeutic contribution. More specifically, this was for his discoveries that synthesized agents that inhibited the actions of various body substances, particularly on the vascular and musculoskeletal systems.

A key scientific discovery in the 1960s was that there was more than one type of histamine receptor, and in 1966, Ash and Schild suggested that the receptor blocked by antihistamines be called the $H_1$ receptor, and agents blocking it be called $H_1$ receptor antagonists.

Second-generation $H_1$ antihistamines were introduced in the 1980s. These agents represented a major enhancement in antihistamine development because they had no or only minimal sedative activity. Furthermore, they were highly selective for $H_1$ receptors and were devoid of anticholinergic activity. However, because of differences in drug specificity for active transporter proteins (eg, P-glycoprotein [$P$-gP]) across the blood–brain barrier, some second-generation agents may enter the CNS to a greater extent than others. Cetirizine, desloratadine, and loratadine, especially at high dosages, are potentially more sedating than fexofenadine and levocetirizine.

Another major drawback for some second-generation agents was documentation in the late 1990s of significant cardiotoxicity. That is, astemizole and terfenadine were shown to block the delayed rectifier $K^+$ current ($I_{Kr}$), which is essential for cardiac repolarization. This gave rise to the potential for QT interval prolongation and life-threatening ventricular arrhythmias such as torsade de pointes. Such cardiotoxic potential is now well established and has been extensively reviewed. In most countries, astemizole and terfenadine have now been withdrawn from the market.

The evolution of second-generation antihistamines was essentially based on experimentation with, and modification of, forerunning first-generation compounds. Further modifications then led to the introduction of other second-generation agents: for example, stereoselective investigation led to levocetirizine, and the knowledge of metabolism pathway of loratadine led to the development of desloratadine. A recent development is the dual platelet activator factor and histamine $H_1$ receptor antagonist rupatadine, which undergoes extensive hepatic metabolism to produce active metabolites, including desloratadine.

However, bilastine (Figure 3) is a novel, benzimidazole–piperidine derivative that is a highly selective $H_1$ antihistamine. Unlike certain other antihistamines, it is a distinct chemical entity and not derived structurally from other compounds in this class. It has been commercially available internationally since March 2011.
Properties of the “ideal” antihistamine

The ARIA guidelines stipulate that before a physician prescribes pharmacotherapy, the following pertinent factors should be considered: the efficacy, safety and cost-effectiveness of treatment, patient preference, the goals of treatment, anticipated adherence to treatment, disease severity, and control, as well as the presence of concurrent conditions. An extension of this is that the guidelines also provide a detailed list of “properties that should be met by oral H<sub>1</sub>-antihistamines” (Table 1). Fundamental among these properties are potent and selective blocking activity at H<sub>1</sub> receptors, a rapid onset and long duration of action, efficacy in allergic rhinoconjunctivitis, and against all symptoms, including nasal obstruction, no interaction with cytochrome P450 (CYP 450), no sedative activity or cognitive or psychomotor impairment, no anticholinergic activity, no cardiac safety concerns, and no potential for tachyphylaxis.

As outlined in the following sections, bilastine – as a modern, second-generation H<sub>1</sub> antihistamine – has the highest number of desired features for a modern antihistamine according to international ARIA guidelines (Table 2).

Table 1 Requirements of the ideal oral H<sub>1</sub> antihistamine

<table>
<thead>
<tr>
<th>Pharmacological properties</th>
<th>Efficacy</th>
<th>Side effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potent and selective activity at H&lt;sub&gt;1&lt;/sub&gt; receptors</td>
<td>Effective in both intermittent and persistent allergic rhinitis</td>
<td>No sedation or cognitive or psychomotor impairment</td>
</tr>
<tr>
<td>Other antiallergic activity</td>
<td>Effective against all nasal symptoms, including obstruction</td>
<td>No anticholinergic activity</td>
</tr>
<tr>
<td>No clinically relevant pharmacokinetic interactions with food, medication, or intestinal proteins</td>
<td>Improves ocular symptoms</td>
<td>No weight gain</td>
</tr>
<tr>
<td>No interaction with cytochrome P450</td>
<td>Studies should be conducted in young children and elderly patients to assess efficacy</td>
<td>No cardiac safety concerns</td>
</tr>
<tr>
<td>No interaction with other diseases (thereby avoiding toxic reactions)</td>
<td></td>
<td>Potential use in pregnancy and breastfeeding</td>
</tr>
</tbody>
</table>

Pharmacodynamics

- Rapid onset of action
- Long duration of action permitting once-daily dosing
- No potential for tolerance development (tachyphylaxis)

## Table 2 Clinical profile differences between various second-generation H<sub>1</sub> antihistamines

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Bilastine</th>
<th>Cetirizine</th>
<th>Desloratadine</th>
<th>Ebastine</th>
<th>Fexofenadine</th>
<th>Levocetirizine</th>
<th>Loratadine</th>
</tr>
</thead>
<tbody>
<tr>
<td>H&lt;sub&gt;1&lt;/sub&gt; receptor selectivity</td>
<td>+++</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Affinity for H&lt;sub&gt;1&lt;/sub&gt; receptors</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>Metabolism</td>
<td>Not metab.</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>t&lt;sub&gt;max&lt;/sub&gt; (hours)</td>
<td>1.3</td>
<td>1.0</td>
<td>3.0</td>
<td>2.6–4.0 (carebastine metabolite)</td>
<td>1–3</td>
<td>0.9</td>
<td>1.0–1.5</td>
</tr>
<tr>
<td>t&lt;sub&gt;1/2&lt;/sub&gt; (hours)</td>
<td>14.5</td>
<td>10.0</td>
<td>27.0</td>
<td>15–19 (carebastine metabolite)</td>
<td>11–15</td>
<td>7.9</td>
<td>8.4</td>
</tr>
<tr>
<td>Indicated for allergic rhinoconjunctivitis?</td>
<td>✓</td>
<td>✓/✗ (some but not all formulations)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Indicated for allergic rhinitis?</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Indicated for urticaria?</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Pediatric indication?</td>
<td>✗ (ongoing studies)</td>
<td>✓ (children 6–12 years)</td>
<td>✓ (children ≥1 year)</td>
<td>✓ (children ≥2 years)</td>
<td>✓ (children ≥3 years)</td>
<td>✓ (children ≥2 years)</td>
<td>✓ (children ≥2 years)</td>
</tr>
<tr>
<td>Dosage adjustment in renal impairment</td>
<td>✗</td>
<td>✓ (in moderate to severe)</td>
<td>Caution (severe impairment)</td>
<td>Caution</td>
<td>x</td>
<td>✓ (in moderate-to-severe)</td>
<td>x</td>
</tr>
<tr>
<td>Dosage adjustment in hepatic impairment</td>
<td>✗</td>
<td>✓ (if concomitant renal dysfunction)</td>
<td>Not mentioned</td>
<td>Caution (in mild to moderate)</td>
<td>x</td>
<td>✓ (if concomitant renal dysfunction)</td>
<td>✓ (severe disease)</td>
</tr>
<tr>
<td>Dosage adjustment in elderly?</td>
<td>✗</td>
<td>✗ (if renal function OK)</td>
<td>Not mentioned</td>
<td>x</td>
<td>x</td>
<td>✓ (for concomitant moderate-to-severe renal impairment)</td>
<td>x</td>
</tr>
<tr>
<td>Interaction with food?</td>
<td>✓ (give on empty stomach)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>Not mentioned</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Use in pregnancy and lactation?</td>
<td>Caution (very limited data)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>Caution</td>
<td>x</td>
</tr>
<tr>
<td>Clinically relevant drug interactions?</td>
<td>✗</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Interaction with alcohol?</td>
<td>Caution</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Can patients drive and operate machinery (ie, lack of sedative potential)?</td>
<td>✓ (caution: drowsiness)</td>
<td>✓ (check drug response when intending to drive)</td>
<td>✓ (caution: drowsiness)</td>
<td>✓ (caution: somnolence)</td>
<td>Not mentioned</td>
<td>✓ (check drug response when intending to drive)</td>
<td>✓ (caution: drowsiness)</td>
</tr>
<tr>
<td>Contraindications</td>
<td>None</td>
<td>Severe renal impairment</td>
<td>None</td>
<td>Severe hepatic impairment</td>
<td>None</td>
<td>Severe renal impairment</td>
<td>None</td>
</tr>
<tr>
<td>Number of ARIA recommended antihistamine properties</td>
<td>10</td>
<td>6</td>
<td>6.5</td>
<td>6.5</td>
<td>9.5</td>
<td>6.5</td>
<td>6.5</td>
</tr>
</tbody>
</table>

### Notes:
- Data obtained from Summary of Product Characteristics for each individual compound (available from [http://www.medicines.org.uk/emc](http://www.medicines.org.uk/emc)).
- Score is derived from ARIA recommended antihistamine properties. (0.5 is given for each characteristic where “caution” is recommended).
- ±, negligible; +, mild; ++, moderate; ++++, marked.

### Abbreviations:
- t<sub>max</sub>, time to peak plasma concentration; t<sub>1/2</sub>, elimination half-life; ARIA, Allergic Rhinitis and its Impact on Asthma; CYP, cytochrome P450.
Reduced microvascular leakage from guinea pig trachea and rat dorsal skin, and reduced histamine-induced bronchospasm and histamine- and compound 48/80-induced lethality in guinea pigs. In these respects, bilastine had effects similar to those of cetirizine but was more potent than fexofenadine. Other antiallergic effects of bilastine were demonstrated in various rodent models. Specifically, bilastine reduced vascular permeability mediated by passive cutaneous anaphylaxis in rats and reduced IgG-dependent active cutaneous anaphylaxis. In mice, bilastine reduced IgE-dependent active cutaneous anaphylaxis and the passive Arthus reaction induced by ovine red blood cells. Again, the magnitude of these effects was similar to that produced by cetirizine and superior to that produced by fexofenadine.

**Pharmacokinetic profile**

Bilastine is rapidly absorbed after oral administration. In rats, its onset of antihistaminic action is ~30 minutes postdose, the maximum clinical effect persists from 30 minutes to 8 hours postdose, and the drug has a prolonged duration of action (≥16 hours; Figure 5).

In healthy volunteers given a single oral dose of bilastine 20 mg, the mean peak plasma concentration ($C_{\text{max}}$) was 220 μg/L, attained at 1.3 hours postdose ($t_{\text{max}}$). The apparent volume of distribution ($V_{\text{d(app)}}$) was 1.29 L/kg, terminal elimination half-life ($t_{1/2}$) was 14.5 hours, and total plasma clearance was 18.1 L/h; bilastine was 84%–90% bound to plasma proteins.

The oral bioavailability of bilastine is ~60%. However, in healthy volunteers given a single 20 mg dose, concurrent food intake reduced bioavailability by 30% (high-fat meal) or 25% (low-fat meal) relative to fasting conditions. Concomitant ingestion of grapefruit juice also reduced bilastine bioavailability by 30%. Therefore, it is recommended that bilastine be taken in the fasting state.

As previously outlined, and as listed in ARIA guidelines, one of the key qualities of an ideal oral H$_1$ antihistamine is to have no interaction with CYP 450. However, some oral H$_1$ antihistamines (eg, loratadine, rupatadine) are extensively transformed to active metabolites by the CYP system in the liver. This creates significant potential for drug–drug interactions. Importantly, bilastine does not interact significantly, either as an inhibitor or as an inducer, with the CYP enzyme system in vitro, and it does not undergo significant metabolism in humans. Approximately 95% of an oral bilastine dose is excreted unchanged in the urine (28%) and feces (67%). This elimination profile markedly reduces the potential for metabolic drug–drug interactions.

Oral bilastine can be administered to patients independently of glomerular filtration rate. No dosage adjustments are needed in patients with mild, moderate, or severe renal impairment. However, in patients with moderate–severe renal insufficiency who are being treated with P-gP inhibitors, such as cyclosporine, diltiazem, erythromycin, ketoconazole, or ritonavir, bilastine should not be administered; these inhibitors may increase plasma bilastine levels and lead to increased potential for adverse events.

As this agent is not metabolized and is excreted largely unchanged, hepatic impairment is not expected to increase systemic exposure above the safety margin of the drug. Therefore, no dosage adjustment is needed in patients with hepatic impairment.

Bilastine is a substrate for several transporter proteins in the P-gp and organic anion-transporter protein class. These transporters have a significant influence on the pharmacokinetics of bilastine.
pharmacokinetic profile of various drugs since P-gp can be considered as an efflux pump, whereas organic anion-transporter proteins can facilitate drug uptake.\(^5\) Bilastine has shown a high affinity for the P-gp efflux pump;\(^5\) this effect restricts transit across the blood–brain barrier and limits the potential for sedation.\(^30,32\)

Differences between the transporter protein-binding profiles of second-generation antihistamines may explain some of the substantial differences in clinical activity and tolerability that exist between agents in this class (Table 2). Further research in this area is clearly warranted. Indeed, transporter protein interactions might ultimately explain important clinical differences, such as the potentially longer duration of action for bilastine over fexofenadine.\(^56\)

### Bilastine efficacy

The bilastine clinical trial program was designed before the publication of the 2001 ARIA guidelines, so the patient inclusion criteria were based on the former classification of seasonal and perennial allergic rhinitis.

### Seasonal allergic rhinitis

In two multicenter, randomized, double-blind, placebo-controlled trials in a total of 1,402 patients with seasonal allergic rhinitis, the efficacy of bilastine was compared with that of cetirizine\(^57\) and desloratadine.\(^58\)

In one trial,\(^57\) over a 2-week treatment period, bilastine and cetirizine displayed similar efficacy: both compounds significantly reduced total symptom score (TSS = nasal symptom score [NSS] + nonnasal symptom score [NNSS]), relative to placebo.\(^57\) The percentage decrease from baseline in NSS (for nasal obstruction, rhinorrhea, sneezing, and itching) was significantly greater (\(P<0.001\)) with bilastine (−42.4%) and cetirizine (−48.2%) than placebo (−26.9%). The same was true for NNSS (for ocular tearing, redness, and itching): corresponding percentage changes from baseline were −49.8%, −51.0%, and −27.6% (Figure 6).\(^57\)

In the other trial,\(^58\) similar results to the first study were obtained for bilastine and desloratadine versus placebo over a 2-week treatment period. Regarding the primary study end point – area under the curve of TSS (TSS\(_{AUC}\)) – the mean value was significantly lower (\(P<0.001\)) for bilastine (98.4) and desloratadine (100.5) than for placebo (118.4).\(^58\)

In a Vienna Challenge Chamber study performed outside the pollen season in 75 individuals with asymptomatic seasonal allergic rhinitis, an antihistamine or placebo was administered immediately before allergen challenge.\(^56\)

The three antihistamines tested, bilastine, cetirizine, and fexofenadine, were all significantly effective (\(P<0.001\)) regarding percentage mean decrease in total NSS versus placebo at all time points, including early (1–4 hours) and late (22–26 hours) after dosing.\(^56\) However, at the latter time point, bilastine (\(P=0.0012\)) and cetirizine (\(P<0.001\)) were both significantly more effective than fexofenadine (Figure 7).\(^57\)

As already mentioned, this suggests that bilastine and cetirizine have a longer duration of action than fexofenadine.\(^56\)

Bilastine is indicated for allergic rhinoconjunctivitis, whereas not all antihistamines have this specific indication (Table 2). An analysis of bilastine clinical trials showed that this agent was significantly more effective than placebo at relieving ocular symptoms (\(P<0.001\)), including both

---

**Figure 6** Percentage decrease from baseline in NSS and NNSS in a randomized, double-blind, placebo-controlled study of bilastine versus cetirizine in patients with seasonal allergic rhinitis.

**Notes:** \(P<0.001\) versus placebo. Data from Kuna et al.\(^57\)

**Abbreviations:** NSS, nasal symptom score; NNSS, nonnasal symptom score.

**Figure 7** Effects of three antihistamines on TNSS in a Vienna Challenge Chamber study performed in 75 individuals with asymptomatic seasonal allergic rhinitis.

**Notes:** \(P<0.001\) versus placebo, \(P=0.0012\) for bilastine versus fexofenadine, \(P<0.001\) for cetirizine versus fexofenadine. Data from Horak et al.\(^56\)

**Abbreviation:** TNSS, total nasal symptom score.
reflexive and instantaneous symptoms (itching, tearing, and conjunctival redness).

**Perennial allergic rhinitis**

A randomized, double-blind, placebo-controlled trial, conducted in Europe, Argentina, and South Africa, compared the efficacy of bilastine with that of cetirizine and placebo over 4 weeks in 651 patients with perennial allergic rhinitis; in an open-label, extension phase, 513 patients were treated with bilastine 20 mg once daily for 12 months, the longest analysis date to date with any antihistamine. There was no statistically significant difference between groups in AUC$_{TSS}$ from baseline to day 28. However, there was a region-specific effect: primary efficacy was significantly better in the antihistamine versus placebo groups in Europe and Argentina ($P=0.039$). Conversely, no significant difference was evident in South Africa, where patients reported a relatively high placebo response rate. During the open-label extension phase, bilastine significantly reduced TSS, NSS, NSS without blocked symptoms, NNSS, and constituent symptoms after both the patients’ and investigators’ assessments. The long-term extension phase of this study also demonstrated that bilastine was safe and well tolerated during extended use.

The proven efficacy of bilastine in perennial allergic rhinitis is important for physicians in the Southeast Asian region, given the high proportion of patients who have persistent allergic rhinitis in this part of the world.

**Urticaria**

A 4-week, multicenter, randomized, double-blind, placebo-controlled study compared the efficacy of bilastine with that of levocetirizine in a total of 525 patients with chronic idiopathic urticaria. Bilastine and levocetirizine were similarly effective and both significantly more effective than placebo (both the patients’ and investigators’ assessments). The long-term extension phase of this study also demonstrated that bilastine was safe and well tolerated during extended use.

The proven efficacy of bilastine in perennial allergic rhinitis is important for physicians in the Southeast Asian region, given the high proportion of patients who have persistent allergic rhinitis in this part of the world.

While spontaneous urticaria is the most common form, –25% of patients with urticaria have an inducible form. Bilastine has been evaluated at a range of doses, from the recommended dose of 20 mg to four times this dosage (ie, 80 mg once daily) in a randomized, double-blind, placebo-controlled, 7-day study in patients with acquired cold urticaria. A response rate (percentage of patients symptom free) of 60% was obtained. The incidence of adverse events at all bilastine doses (20 mg, 40 mg, and 80 mg) was similar to placebo, demonstrating that bilastine is well tolerated even at doses two or four times higher than the recommended daily dose. Further research is needed to demonstrate its efficacy in other inducible forms of urticaria, which may include urticaria induced by pressure, heat, sun exposure, exercise, or contact with specific allergens.

The use of supratherapeutic doses of bilastine in the study of patients with cold urticaria is consistent with international guideline recommendations. Joint guidelines from the European Academy of Allergy and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO) now clearly stipulate that “modern second generation H$_1$-antihistamines are to be used as first line treatment of urticaria.” In addition, these guidelines recommend “a trial of up to fourfold dose of modern second generation H$_1$-antihistamines as second-line in the algorithm of treatment.” The aim of this recommendation is to attain complete control of symptoms since more than one-third of patients with chronic urticaria are refractory to standard-dosage antihistamine therapy.
A comparison of clinical trial data for second-generation antihistamines in chronic urticaria suggests that this bilastine dosage (80 mg/d) is significantly more effective than supratherapeutic dosages of desloratadine and levocetirizine (Figure 9). However, use of these compounds at four times higher than standard doses is certain to raise safety concerns among some physicians. For instance, the sedative potential of cetirizine, desloratadine, and loratadine will likely be markedly greater than that of bilastine, fexofenadine, and levocetirizine. Concerns at high dosage may also manifest about the potential for QTc prolongation, particularly given the unfavorable history of astemizole and terfenadine. However, bilastine at therapeutic and supratherapeutic doses in healthy volunteers had no significant influence on ventricular repolarization. Bilastine doses of 20 mg and 100 mg had no clinically significant effect on QTc interval. Bilastine 20 mg was also administered with ketoconazole and had no effect on QTc interval when used in combination.

**Bilastine safety**

The safety database for bilastine comprises >5,000 individuals involved in well-designed clinical trials. A total of >3,000 patients were treated with bilastine, generally at a dosage of 20 mg once daily for 2–4 weeks. The incidence of treatment-related adverse events was not markedly different between bilastine (12.7%), placebo (12.8%), and other antihistamines: cetirizine (14.3%), desloratadine (11.6%), and levocetirizine (15.8%).

In the pooled analysis of adverse events, the incidence of treatment-related CNS events was similar between bilastine, fexofenadine, and levocetirizine. Concerns at high dosage may also manifest about the potential for QTc prolongation, particularly given the unfavorable history of astemizole and terfenadine. However, bilastine at therapeutic and supratherapeutic doses in healthy volunteers had no significant influence on ventricular repolarization. Bilastine doses of 20 mg and 100 mg had no clinically significant effect on QTc interval. Bilastine 20 mg was also administered with ketoconazole and had no effect on QTc interval when used in combination.

The CNS effects of bilastine 80 mg were also evaluated in healthy volunteers. Although objective test results (d2 cancellation test, simple reaction time) revealed minor – yet significant – impairment, high-dosage bilastine did not significantly alter subjective test results (visual analog scale score, Profile of Mood States questionnaire score). The effects of bilastine 80 mg were equivalent to those of standard-dose hydroxyzine.

**Lack of sedation**

In several studies utilizing an active control “arm” comprising the first-generation agent hydroxyzine, standard-dosage bilastine (20 mg once daily) and higher-dosage bilastine (40 mg once daily in one study and a single 80 mg dose in another) had no significant effects on various objective measures of psychomotor and driving performance. Moreover, when bilastine was administered concurrently with lorazepam, the extent of psychomotor impairment was similar to that when lorazepam was administered alone. Also, no interaction has been identified between alcohol and standard-dosage bilastine. Objective testing in a placebo-controlled trial revealed an extent of psychomotor impairment with bilastine 20 mg + alcohol similar to that noted after ingestion of alcohol alone, whereas standard doses of either hydroxyzine or cetirizine exacerbated the impairing effects of alcohol on psychomotor performance.

A positron emission tomography study of brain H1 receptor occupancy in 12 healthy volunteers revealed that this...
parameter was close to zero for bilastine (−3.92%), and therefore similar to placebo. Conversely, the first-generation agent hydroxyzine had significantly greater occupancy (+54%).

This confirms that bilastine has relatively limited potential to cross the blood–brain barrier and interact with CNS H₁ receptors. Based on published data for other agents, it appears that bilastine has the lowest rate of brain H₁ receptor occupancy of all the available antihistamines (Table 3).

Therefore, it has minimal capacity to cause CNS adverse effects.

**No QTc prolongation**

The cardiac safety profile of bilastine was confirmed in various studies that included concurrent administration of the CYP450/P-gP inhibitors ketoconazole, erythromycin, and diltiazem and in detailed QT studies conducted in accordance with International Conference on Harmonization (ICH) guidelines. To date, bilastine is the only commercially available antihistamine that has been tested using the stringent ICH E14 criteria for effects on QT interval. This study showed no significant effect on QTc interval using these stringent criteria. These studies confirmed that standard-dose bilastine has a good cardiac safety profile and that uptitration of the bilastine dose to 220 mg, or administration of the drug with CYP450 or P-gP inhibitors, does not alter this safety profile.

In clinical trials, bilastine was not associated with any clinically relevant QTc interval prolongation.

**Bilastine administration in children**

The efficacy and safety of bilastine in children aged 12 years or less, who frequently have allergic disorders, have not yet been established. For registration of the adult formulation of bilastine, the clinical plan was developed to comply with the European Medicines Agency guidelines and therefore the cut off age is 12 years. However, bilastine has been investigated according to a Paediatric Investigation Plan that was designed according to the requirements of the European Medicines Agency Paediatric Committee. Publication of data from the Paediatric Investigation Plan is awaited with interest.

**Conclusion**

Currently, there are a number of unmet needs in the management of allergic conditions in Asia Pacific, with many patients still experiencing sedation from the use of older antihistamines. When second-generation H₁ antihistamines were introduced in the 1980s, they revolutionized the treatment of allergic disorders because of a lack of, or only minimal, sedative potential.

The proven efficacy and safety profile of bilastine, its low potential for CNS impairment when coadministered with alcohol or for metabolic drug–drug interactions, and no need for dose adjustments confirm that this compound has a forerunning place in therapy among second-generation H₁ antihistamines in the management of urticaria and allergic rhinitis, including allergic rhinoconjunctivitis (intermittent and persistent).

**Acknowledgments**

The authors would like to acknowledge Menarini Asia-Pacific Holdings Pte Ltd for providing logistic support and funding for the consensus meeting and for commissioning MIMS Pte Ltd to provide writing assistance and editorial support. The views expressed in this manuscript are solely those of the authors.

**Disclosure**

The authors report no conflicts of interest in this work.

**Table 3** Percentage of brain H₁ receptor occupancy (mean) after oral administration of antihistamines using PET

<table>
<thead>
<tr>
<th>Antihistamine</th>
<th>Dose (mg)</th>
<th>Mean H₁ receptor occupancy on PET (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bilastine</td>
<td>20</td>
<td>−3.92</td>
</tr>
<tr>
<td>Fexofenadine</td>
<td>120</td>
<td>−0.1</td>
</tr>
<tr>
<td>Ebastine</td>
<td>10</td>
<td>9.9−14.4</td>
</tr>
<tr>
<td>Terfenadine</td>
<td>60</td>
<td>12.1−17.2</td>
</tr>
<tr>
<td>Azelastine</td>
<td>1</td>
<td>20.3</td>
</tr>
<tr>
<td>Cetirizine</td>
<td>20</td>
<td>26.0</td>
</tr>
<tr>
<td>d-Chlorpheniramine</td>
<td>1</td>
<td>40.4</td>
</tr>
<tr>
<td>Hydroxyzine</td>
<td>25</td>
<td>53.95</td>
</tr>
<tr>
<td>d-Chlorpheniramine</td>
<td>2</td>
<td>60.4−76.8</td>
</tr>
</tbody>
</table>

Abbreviation: PET, positron emission tomography.

**References**


40. Wallace DV, Dykewicz MS, Bernstein DI, et al; Joint Task Force on Practice; American Academy of Allergy; Asthma & Immunology; American College of Allergy; Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of rhinitis: an updated practice parameter. *J Allergy Clin Immunol*. 2008;122(2 suppl):S1–S84.


